Status:
COMPLETED
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
Immunex Corporation
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists.
- Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option:
- Non-Small Cell Lung
- Breast
- Head and Neck
- Esophageal
- Stomach
- Ovarian carcinomas
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- Life expectancy of at least 12 weeks.
- Must have adequate organ function
- Peripheral Neuropathy must be less than Grade 2
Exclusion
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00201812
Start Date
November 1 2000
End Date
May 1 2005
Last Update
December 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Medical Center
Columbus, Ohio, United States, 43210